AI Tools Show Early Promise Across Drug Discovery, Clinical Decision-Making in Lung Cancer

AI-designed drugs show phase 1 success rates of 80–90% (vs. conventional 40–65%) and roughly double the probability of reaching market (5–10% to 9–18%). Autonomous clinical agents and explainable AI tools are improving physician decision-making in lung cancer, with the first CE-certified generative AI medical device now in use in the EU.

This Wire brief sits within Fusion42's coverage of Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.